Omnicell, Inc. (NASDAQ:OMCL) Given Average Recommendation of “Hold” by Analysts

Shares of Omnicell, Inc. (NASDAQ:OMCL) have earned an average recommendation of “Hold” from the seven analysts that are covering the firm, Marketbeat reports. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $37.83.

A number of analysts have weighed in on the stock. Wells Fargo & Company raised their price objective on shares of Omnicell from $26.00 to $30.00 and gave the stock an “equal weight” rating in a report on Friday, August 2nd. Bank of America raised their target price on shares of Omnicell from $34.00 to $44.00 and gave the company a “buy” rating in a research note on Friday, August 2nd. Benchmark restated a “buy” rating and set a $38.00 price objective on shares of Omnicell in a report on Monday, July 15th. Barclays raised shares of Omnicell from an “underweight” rating to an “equal weight” rating and lifted their price objective for the stock from $26.00 to $39.00 in a report on Friday, August 2nd. Finally, StockNews.com lowered shares of Omnicell from a “buy” rating to a “hold” rating in a research note on Tuesday, July 16th.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Strs Ohio raised its position in Omnicell by 28.2% in the 4th quarter. Strs Ohio now owns 5,000 shares of the company’s stock valued at $188,000 after buying an additional 1,100 shares during the last quarter. California Public Employees Retirement System grew its holdings in Omnicell by 11.7% during the fourth quarter. California Public Employees Retirement System now owns 75,523 shares of the company’s stock worth $2,842,000 after buying an additional 7,902 shares in the last quarter. Avory & Company LLC grew its stake in Omnicell by 25.6% in the 4th quarter. Avory & Company LLC now owns 193,162 shares of the company’s stock valued at $7,269,000 after purchasing an additional 39,386 shares during the period. Victory Capital Management Inc. boosted its position in Omnicell by 465.1% during the fourth quarter. Victory Capital Management Inc. now owns 44,766 shares of the company’s stock worth $1,685,000 after purchasing an additional 36,844 shares during the period. Finally, Summit Global Investments grew its position in Omnicell by 24.9% during the fourth quarter. Summit Global Investments now owns 20,855 shares of the company’s stock worth $785,000 after buying an additional 4,158 shares in the last quarter. Institutional investors own 97.70% of the company’s stock.

Omnicell Price Performance

Shares of Omnicell stock opened at $44.80 on Monday. The stock’s fifty day moving average is $32.22 and its 200 day moving average is $29.96. The stock has a market cap of $2.06 billion, a P/E ratio of -97.39, a P/E/G ratio of 83.06 and a beta of 0.80. Omnicell has a one year low of $25.12 and a one year high of $61.44. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.22 and a current ratio of 2.45.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings data on Thursday, August 1st. The company reported $0.51 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.14 by $0.37. Omnicell had a negative net margin of 1.92% and a positive return on equity of 2.52%. The firm had revenue of $276.80 million for the quarter, compared to the consensus estimate of $254.41 million. During the same period last year, the firm earned $0.29 earnings per share. The company’s quarterly revenue was down 7.4% on a year-over-year basis. Sell-side analysts anticipate that Omnicell will post 0.36 earnings per share for the current year.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.